GLUE · Monte Rosa Therapeutics, Inc. · Investor Relations

$11.22 -0.14 (-1.23%) At close · Oct 21

Russell 2000 member Rebalance outlook locked

Market Cap

$957.22M

85.31M

Volume · Oct 21 1.08M Avg daily vol (3M) 1.38M

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Past events

Date	Event	Type
2026-10-01	MRT-8102 GFORCE-1 Clinical Study Results	Event
2026-07-01	MRT-8102 Phase 1 Clinical Data Update	Event
2026-04-21	AACR 2026 – Selective targeting of CCNE1 using molecular glue degraders for the treatment of CCNE1 amplified cancers	Event
2026-02-26	ASCO Genitourinary Cancers Symposium Presentation	Presentation
2026-01-22	Keystone Symposia – MRT-6160, a highly selective and first-in-class VAV1-directed molecular glue degrader, demonstrates activity in multiple immune-mediated disease models	Event
2026-01-20	Nature Structural & Molecular Biology – Cereblon induces G3BP2 neosubstrate degradation using molecular surface mimicry	Event
2026-01-10	MRT-8102 GFORCE-1 Clinical Study Results	Event
2026-01-07	Earnings conference call (announced in 8-K)	Earnings call
2025-12-16	MRT-2359 Phase 1/2 Clinical Data Up2025-12-16	Event
2025-11-08	AHA Scientific Sessions 2025 – Selective Degradation of NIMA-related kinase 7 (NEK7) via a Molecular Glue Degrader Inhibits IL-1 Downstream of NLRP3 Inflammasome Activation: A Novel Therapeutic Approach for Cardiovascular Inflammation	Event
2025-10-26	ACR Convergence 2025 – MRT-6160, a VAV1-directed molecular glue degrader, attenuates T and B cell effector functions and inhibits disease progression in a spontaneous autoimmune MRL-Faslpr mouse model	Event
2025-09-25	ECTRIMS 2025 – MRT-6160, a VAV1-Directed Molecular Glue Degrader, Inhibits Disease Progression in a Preclinical Model of T/B-cell Mediated Experimental Autoimmune Encephalomyelitis	Event
2025-07-03	Science – Mining the CRBN Target Space Redefines Rules for Molecular Glue-induced Neosubstrate Recognition	Event
2025-06-25	FOCIS 2025 – MRT-6160, a VAV1-Directed Molecular Glue Degrader, Inhibits Disease Progression in a Preclinical Model of T/B-cell Mediated Experimental Autoimmune Encephalomyelitis	Event
2025-06-16	EULAR 2025 – Targeting NLRP3 Inflammasome Activation and Inflammation in Gout with NEK7 Molecular Glue Degraders: A Novel Therapeutic Strategy	Event
2025-04-28	AACR 2025 – Selective Targeting of CDK2 Using Molecular Glue Degraders for the Treatment of HR-Positive/HER2-Negative Breast Cancer	Event
2025-03-20	Monte Rosa Pipeline Update and Clinical Results Presentation (March 20, 2025)	Presentation
2025-03-07	Science – Mining the CRBN Target Space Redefines Rules for Molecular Glue-induced Neosubstrate Recognition	Event
2025-02-18	Keystone Symposia – Mining the CRBN Target Space Redefines Rules of Neosubstrate Engagement	Event
2024-12-11	San Antonio Breast Cancer Symposium – Selective Targeting of CDK2 Using Molecular Glue Degraders for the Treatment of HR-Positive/HER2-Negative Breast Cancer	Event
2024-11-12	San Antonio Breast Cancer Symposium – Selective Targeting of CDK2 Using Molecular Glue Degraders for the Treatment of HR-Positive/HER2-Negative Breast Cancer	Event
2024-11-09	6th Annual Inflammasome Summit – Exploring Novel Modalities: Disabling the NLRP3 Inflammasome with a NEK7 Molecular Glue Degrader	Event
2024-10-30	7th Annual TPD & Induced Proximity Summit – Molecular Glue Degraders: From the Bench to the Clinic	Event
2024-10-29	7th Annual TPD & Induced Proximity Summit – Rational Design of Selective CDK2 and Cyclin E1 MGDs	Event
2024-10-23	Selective Targeting of Cyclin E1 Using Molecular Glue Degraders in CCNE1 Amplified Solid Malignancies	Event

Source: https://ir.monterosatx.com/

Key facts CIK 1826457 CUSIP 61225M102 13F (30d) 15 filings 15 filers Visit website Investor relations